Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocumension TherapeuticsOCUTF 53 Cash-to-Debt is 2.92 as of Dec. 2025, which is 95% below its 10-year median of 62.59. GuruFocus rates OCUTF with a GF Score™ of 53/100 and a GF Value™ of $2.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,401 Biotechnology companies, Ocumension Therapeutics ranks worse than 62.17% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ocumension Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 2.92.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ocumension Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Ocumension Therapeutics's Cash-to-Debt or its related term are showing as below:
OCUTF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.92 Med: 62.59 Max: 991.35
Current: 2.92
During the past 8 years, Ocumension Therapeutics's highest Cash to Debt Ratio was 991.35. The lowest was 2.92. And the median was 62.59.
OCUTF's Cash-to-Debt is ranked worse than 62.17% of 1401
companies
in the Biotechnology industry
Industry Median: 6.56
vs OCUTF: 2.92
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ocumension Therapeutics Cash-to-Debt Related Terms
Ocumension Therapeutics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OCUTF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (OCUTF) has a Cash-to-Debt of 2.92 as of Dec. 2025. This is 95% below median its historical median of 62.59. Over the past decade, Ocumension Therapeutics' Cash-to-Debt has ranged from 2.92 to 991.35. According to the industry distribution chart, Ocumension Therapeutics ranks #871 out of 1401 companies in the Biotechnology industry, placing it in the top 62.2%.
Is Ocumension Therapeutics' Cash-to-Debt too high?
Ocumension Therapeutics' current Cash-to-Debt of 2.92 is 95% below median its 10-year median of 62.59. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 991.35. The Biotechnology industry median Cash-to-Debt is 6.56. Ocumension Therapeutics' value of 2.92 is 55.5% below this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #871 out of 1401 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #871 out of 1401 companies for Cash-to-Debt. This places Ocumension Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.56. Ocumension Therapeutics' value of 2.92 is 55.5% below this benchmark. Historically, Ocumension Therapeutics' own Cash-to-Debt has ranged from 2.92 to 991.35 over the past decade. While the company's 10-year median is 62.59 vs. the industry median of 6.56, Ocumension Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.56, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current Cash-to-Debt of 2.92 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Cash-to-Debt is 2.92, which is 95% below median its own 10-year median of 62.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.61, compared to a current price of $0.70 — trading 73.2% below its estimated fair value. The current Cash-to-Debt is 2.92, which is 95% below median its 10-year median of 62.59 and 55.5% below the Biotechnology industry median of 6.56. Ocumension Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Cash-to-Debt is 2.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 73.2% below its estimated GF Value™ of $2.61.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
Cash-to-Debt: 2.92 (95% below median its 10-year median of 62.59)
GF Value™: $2.61 vs. price of $0.70 (73.2% below fair value)
Industry Position: 55.5% below the Biotechnology median (#871 of 1401)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
53GF Score
Get the complete analysis for OCUTF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
